How To Conduct Controlled Medical Research In A Lab
Conducting controlled medical research in a laboratory is a meticulous and essential aspect of advancing our understanding of health and disease. It allows researchers to
Florida / New York
Ph: 561.316.3330
Medical Device News Magazine reports breaking biotechnology news including new biotech developments, pharmaceuticals and more.
Conducting controlled medical research in a laboratory is a meticulous and essential aspect of advancing our understanding of health and disease. It allows researchers to
“Dosing the first patient, on time, is a testament to our commitment to the clinical development of DA-1241 in patients with NASH,” stated Hyung Heon Kim, President and Chief Executive Officer of NeuroBo. “Based on the pre-clinical and clinical evidence generated to date, DA-1241 has demonstrated reduced hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control, and was shown to be well tolerated in both healthy volunteers and in patients with type 2 diabetes mellitus (T2DM). Given this data, we believe that the mechanism of action of this promising cardiometabolic asset will translate into a safe and effective treatment for NASH, a disease with no current treatment options. The two-part design of this trial provides optionality for a potential interim analysis in the first half of 2024 and we expect to report the full data in the second half of 2024.”
The “U.S. Market Gateway Accelerator for BioSciences and MedTech”, sponsored by WorldUpstart, LLC, is an acceleration program that provides medical tech and life sciences startups with a proven track record outside the U.S. with the opportunity to enter and grow their business in the U.S. market.
“Immune System is an innovative Open Access journal, welcoming articles with a broad background from basic science to clinical research, as long as the manuscript focuses on certain aspects of our immune response,” states editor-in-chief Désirée Larenas-Linnemann.”
Moshe Zilversmit, Co-Founder and CEO of Signum Surgical, commented: “The completion of our clinical trial marks a significant milestone for Signum Surgical and our BioHealxTM device. We look forward to submitting our De Novo classification request to the U.S. FDA and the scientific publication of the data in due course, as we seek to bring this novel treatment to market for the benefit of patients, surgeons, and the healthcare system.”
Associate Professor Eunah Kang and Mr. Youngjun Kim from the School of Chemical Engineering and Material Science at Chung-Ang University, Korea have recently come up with an elegant solution. The duo has developed an electrochemical DNA biosensor using a graphitic nano-onion/molybdenum disulfide (MoS2) nanosheet composite, which effectively detects human papillomavirus (HPV)-16 and HPV-18, and can serve as an early diagnosis of cervical cancer.
Copyright © 2025 Medical Device News Magazine, a division of PTM Healthcare Marketing, Inc. All Rights Reserved
Hours:
M – F 8 am – 5 pm
Florida / New York
Phone: 561.316.3330